|
1
|
Zhu ZF, Li JJ, Liu J, Tang TT, Ding YJ,
Liao YH, Cheng X and Wang X: Circulating Th17 cells are not
elevated in patients with chronic heart failure. Scand Cardiovasc
J. 46:295–300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tang TT, Zhu ZF, Wang J, Zhang WC, Tu X,
Xiao H, Du XL, Xia JH, Dong NG, Su W, et al: Impaired thymic export
and apoptosis contribute to regulatory T-cell defects in patients
with chronic heart failure. PloS One. 6:e242722011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lichtman AH: The heart of the matter:
Protection of the myocardium from T cells. J Autoimmun. 45:90–96.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haugen E, Gan LM, Isic A, Skommevik T and
Fu M: Increased interleukin-6 but not tumour necrosis factor-alpha
predicts mortality in the population of elderly heart failure
patients. Exp Clin Cardiol. 13:19–24. 2008.PubMed/NCBI
|
|
5
|
Fritzenwanger M, Jung C, Franz M, Foerster
M and Figulla HR: Immunomodulatory effects of cardiotrophin-1 on in
vitro cytokine production of monocytes & CD4 + T-lymphocytes.
Indian J Med Res. 136:471–476. 2012.PubMed/NCBI
|
|
6
|
Reifenberg K, Lehr HA, Torzewski M, Steige
G, Wiese E, Küpper I, Becker C, Ott S, Nusser P, Yamamura K, et al:
Interferon-gamma induces chronic active myocarditis and
cardiomyopathy in transgenic mice. Am J Pathol. 171:463–472. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ,
Tang TT, Yao R, Chen Y and Liao YH: The Th17/Treg imbalance in
patients with acute coronary syndrome. Clin immunol. 127:89–97.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stumpf C, Lehner C, Yilmaz A, Daniel WG
and Garlichs CD: Decrease of serum levels of the anti-inflammatory
cytokine interleukin-10 in patients with advanced chronic heart
failure. Clin Sci. 105:45–50. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pudil R, Tichý M, Andrýs C, Rehácek V,
Bláha V, Vojácek J and Palicka V: Plasma interleukin-6 level is
associated with NT-proBNP level and predicts short and long term
mortality in patients with acute heart failure. Acta Medica (Hradec
Kralove). 53:225–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hofmann U and Frantz S: How can we cure a
heart ‘in flame’? A translational view on inflammation in heart
failure. Basic Res Cardiol. 108:3562013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiang F, Guo X, Chen W, Wang J, Zhou T,
Huang F, Cao C and Chen X: Proteomics analysis of human pericardial
fluid. Proteomics. 13:2692–2695. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Frohlich GM, Keller P, Schmid F, Wolfrum
M, Osranek M, Falk C, Noll G, Enseleit F, Reinthaler M, Meier P, et
al: Haemodynamically irrelevant pericardial effusion is associated
with increased mortality in patients with chronic heart failure.
Eur Heart J. 34:1414–1423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hunt SA, Abraham WT, Chin MH, Feldman AM,
Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K,
et al: 2009 focused update incorporated into the ACC/AHA 2005
guidelines for the diagnosis and management of heart failure in
adults: A report of the American college of cardiology
foundation/American heart association task force on practice
guidelines: Developed in collaboration with the International
society for heart and lung transplantation. Circulation.
119:e391–e479. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eren M: Diagnosis and treatment of acute
and chronic heart failure: What has changed in the new European
society of cardiology guideline 2008. Turk Kardiyol Dern Ars.
37:295–300. 2009.PubMed/NCBI
|
|
15
|
Cheitlin MD, Armstrong WF, Aurigemma GP,
Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD,
Kimball TR, et al: ACC/AHA/ASE 2003 guideline update for the
clinical application of echocardiography: Summary article: A report
of the American college of cardiology/American heart association
task force on practice guidelines (ACC/AHA/ASE committee to update
the 1997 guidelines for the clinical application of
echocardiography). Circulation. 108:1146–1162. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hurst JW: The value of using the entire
New York heart association's classification of heart and vascular
disease. Clin Cardiol. 29:415–417. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hunt SA, Abraham WT, Chin MH, Feldman AM,
Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K,
et al: ACC/AHA 2005 guideline update for the diagnosis and
management of chronic heart failure in the adult: A report of the
American college of cardiology/American heart association task
force on practice guidelines (writing committee to update the 2001
guidelines for the evaluation and management of heart failure):
Developed in collaboration with the American college of chest
physicians and the international society for heart and lung
transplantation: Endorsed by the heart rhythm society. Circulation.
112:e154–e235. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li L, Chen W, Zhu Y, Wang X, Jiang DS,
Huang F, Wang L, Xiang F, Qin W, Wang Q, et al: Caspase recruitment
domain 6 protects against cardiac hypertrophy in response to
pressure overload. Hypertension. 64:94–102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao C, Zhu Y, Chen W, Li L, Qi Y, Wang X,
Zhao Y, Wan X and Chen X: IKKe knockout prevents high fat diet
induced arterial atherosclerosis and NF-kB signaling in mice. PloS
One. 8:e649302013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cao C, Li L, Chen W, Zhu Y, Qi Y, Wang X,
Wan X and Chen X: Deficiency of IKKe inhibits inflammation and
induces cardiac protection in high-fat diet-induced obesity in
mice. Int J Mol Med. 34:244–252. 2014.PubMed/NCBI
|
|
21
|
Ziaeian B and Fonarow GC: Epidemiology and
aetiology of heart failure. Nat Rev Cardiol. 13:368–378. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Askevold ET, Nymo S, Ueland T, Gravning J,
Wergeland R, Kjekshus J, Yndestad A, Cleland JG, McMurray JJ,
Aukrust P and Gullestad L: Soluble glycoprotein 130 predicts fatal
outcomes in chronic heart failure: Analysis from the Controlled
Rosuvastatin multinational trial in heart failure (CORONA). Circ
Heart Fail. 6:91–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanda T and Takahashi T: Interleukin-6 and
cardiovascular diseases. Jpn Heart J. 45:183–193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maeda K, Tsutamoto T, Wada A, Mabuchi N,
Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T and
Kinoshita M: High levels of plasma brain natriuretic peptide and
interleukin-6 after optimized treatment for heart failure are
independent risk factors for morbidity and mortality in patients
with congestive heart failure. J Am Coll Cardiol. 36:1587–1593.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maries L and Manitiu I: Diagnostic and
prognostic values of B-type natriuretic peptides (BNP) and
N-terminal fragment brain natriuretic peptides (NT-pro-BNP).
Cardiovasc J Afr. 24:286–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Toufan M, Namdar H, Abbasnezhad M,
Habibzadeh A, Esmaeili H, Yaraghi S and Samani Z: Diagnostic values
of plasma, fresh and frozen urine NT-proBNP in heart failure
patients. J Cardiovasc Thorac Res. 6:111–115. 2014.PubMed/NCBI
|
|
27
|
Chang HR, Hsieh JC, Hsu BG, Wang LY, Chen
MY and Wang JH: Inverse association of N-terminal pro-B-type
natriuretic peptide with metabolic syndrome in patients with
congestive heart failure. PloS One. 8:e790962013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Taylor CJ, Roalfe AK, Iles R and Hobbs FD:
The potential role of NT-proBNP in screening for and predicting
prognosis in heart failure: A survival analysis. BMJ Open.
4:e0046752014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Szczurek W and Szyguła-Jurkiewicz BS:
Oxidative stress and inflammatory markers - the future of heart
failure diagmostics? Kardiochir Torakochirurgia Pol. 2015:145–149.
2015.
|
|
30
|
Gruson D, Ahn SA and Rousseau MF:
Biomarkers of inflammation and cardiac remodeling: The quest of
relevant companions for the risk stratification of heart failure
patients is still ongoing. Biochem Med (Zagreb). 21:254–263. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hoare GS, Birks EJ, Bowles C, Marczin N
and Yacoub MH: In vitro endothelial cell activation and
inflammatory responses in end-stage heart failure. J Appl Physiol
(1985). 101:1466–1473. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ruiz-Ruiz FJ, Ruiz-Laiglesia FJ,
Lasierra-Diaz P, Legarre Samperiz P, Morales-Rull JL,
Sánchez-Marteles M, Amores M and Perez-Calvo JI: Lack of clinical
usefulness of interleukin-6 in long-term follow-up of acutely
decompensated heart failure. Singapore Med J. 48:532–536.
2007.PubMed/NCBI
|
|
33
|
Rumalla VK, Calvano SE, Spotnitz AJ,
Krause TJ, Hilkert RJ, Lin E and Lowry SF: Alterations in
immunocyte tumor necrosis factor receptor and apoptosis in patients
with congestive heart failure. Ann Surg. 236:254–260. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Okamoto N, Noma T, Ishihara Y, Miyauchi Y,
Takabatake W, Oomizu S, Yamaoka G, Ishizawa M, Namba T, Murakami K,
et al: Prognostic value of circulating regulatory T cells for
worsening heart failure in heart failure patients with reduced
ejection fraction. Int Heart J. 55:271–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tang TT, Ding YJ, Liao YH, Yu X, Xiao H,
Xie JJ, Yuan J, Zhou ZH, Liao MY, Yao R, et al: Defective
circulating CD4CD25+Foxp3+CD127(low) regulatory T-cells in patients
with chronic heart failure. Cell Physiol Biochem. 25:451–458. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gandolfo MT, Jang HR, Bagnasco SM, Ko GJ,
Agreda P, Satpute SR, Crow MT, King LS and Rabb H:
Foxp3+ regulatory T cells participate in repair of
ischemic acute kidney injury. Kidney Int. 76:717–729. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yndestad A: Enhanced expression of
inflammatory cytokines and activation markers in T-cells from
patients with chronic heart failure. Cardiovasc Res. 60:141–146.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fritzenwanger M, Jung C, Franz M, Foerster
M and Figulla HR: Immunomodulatory effects of cardiotrophin-1 on in
vitro cytokine production of monocytes & CD4 + T-lymphocytes.
Indian J Med Res. 136:471–476. 2012.PubMed/NCBI
|
|
39
|
Yndestad A, Damås JK, Oie E, Ueland T,
Gullestad L and Aukrust P: Systemic inflammation in heart
failure-the whys and wherefores. Heart Fail Rev. 11:83–92. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cappuzzello C, Di Vito L, Melchionna R,
Melillo G, Silvestri L, Cesareo E, Crea F, Liuzzo G, Facchiano A,
Capogrossi MC and Napolitano M: Increase of plasma IL-9 and
decrease of plasma IL-5, IL-7, and IFN-γ in patients with chronic
heart failure. J Transl Med. 9:282011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fukunaga T, Soejima H, Irie A, Sugamura K,
Oe Y, Tanaka T, Kojima S, Sakamoto T, Yoshimura M, Nishimura Y and
Ogawa H: Expression of interferon-gamma and interleukin-4
production in CD4+ T cells in patients with chronic
heart failure. Heart Vessels. 22:178–183. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fairweather D, Frisancho-Kiss S, Yusung
SA, Barrett MA, Davis SE, Gatewood SJ, Njoku DB and Rose NR:
Interferon-gamma protects against chronic viral myocarditis by
reducing mast cell degranulation, fibrosis and the profibrotic
cytokines transforming growth factor-beta 1, interleukin-1 beta,
and interleukin-4 in the Heart. Am J Pathol. 165:1883–1894. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hilfiker-Kleiner D, Shukla P, Klein G,
Schaefer A, Stapel B, Hoch M, Müller W, Scherr M, Theilmeier G,
Ernst M, et al: Continuous glycoprotein-130-mediated signal
transducer and activator of transcription-3 activation promotes
inflammation, left ventricular rupture, and adverse outcome in
subacute myocardial infarction. Circulation. 122:145–155. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kinugawa T, Kato M, Yamamoto K, Hisatome I
and Nohara R: Proinflammatory cytokine activation is linked to
apoptotic mediator, soluble Fas level in patients with chronic
heart failure. Int Heart J. 53:182–186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Júnior ML Jr, Lopes RD, Seelaender MC and
Lopes AC: Anti-inflammatory effect of physical training in heart
failure role of TNF-alpha and IL-10. Arq Bras Cardiol. 93:643–651.
2009.PubMed/NCBI
|
|
46
|
Amir O, Rogowski O, David M, Lahat N,
Wolff R and Lewis BS: Circulating interleukin-10: Association with
higher mortality in systolic heart failure patients with elevated
tumor necrosis factor-alpha. Isr Med Assoc J. 12:158–162.
2010.PubMed/NCBI
|
|
47
|
Ritschel VN, Seljeflot I, Arnesen H,
Halvorsen S, Weiss T, Eritsland J and Andersen GØ: IL-6 signalling
in patients with acute ST-elevation myocardial infarction. Results
Immunol. 4:8–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pudil R, Tichý M, Andrýs C, Rehácek V,
Bláha V, Vojácek J and Palicka V: Plasma interleukin-6 level is
associated with NT-proBNP level and predicts short- and long-term
mortality in patients with acute heart failure. Acta Medica (Hradec
Kralove). 53:225–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fischer P and Hilfiker-Kleiner D: Role of
gp130-mediated signalling pathways in the heart and its impact on
potential therapeutic aspects. Br J Pharmacol. 153:(Suppl 1).
S414–S427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Richter B, Koller L, Hohensinner PJ, Zorn
G, Brekalo M, Berger R, Mörtl D, Maurer G, Pacher R, Huber K, et
al: A multi-biomarker risk score improves prediction of long-term
mortality in patients with advanced heart failure. Int J Cardiol.
168:1251–1257. 2013. View Article : Google Scholar : PubMed/NCBI
|
